AVRO News and Press, AVROBIO Inc. From 05/13/20

Thinly traded AVROBIO (NASDAQ: AVRO ) jumps  4%  premarket on light volume in reaction to updated data  from a Phase 2 study evaluating its AVR-RD-01 gene therapy in patients with Fabry disease , an inherited disorder characterized by the buildup of a type of fat in the bo...

Sustained enzyme activity up to 22 months and consistent trends demonstrated across multiple other measures in first patient in Fabry disease Phase 2 clinical trial Data from first patient treated using plato TM gene therapy platform in Fabry disease trial show: 43-percen...

Avrobio Collaborates with Magenta Therapeutics for Advancing Novel ADC Avrobio Inc. ( AVRO ) announced its latest collaboration with Magenta Therapeutics ( MGTA ) for advancing the latter's lead drug candidate MGTA-117. The tie-up will provide synergies for both the companies as Avrobio pr...

AVROBIO (NASDAQ: AVRO ): Q1 GAAP EPS of -$0.77. More news on: AVROBIO, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Three oral presentations accepted on new clinical and preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 23rd annual meeting Completed two collaboration agreements to reinforce technological leadership in lentiviral gene therapy Raised $100 million in gross...

AVROBIO (NASDAQ: AVRO ) inks an agreement with Magenta Therapeutics (NASDAQ: MGTA ) to evaluate the potential utility of using the latter's antibody-drug conjugate MGTA-117 for conditioning patients before they receive one of the former's investigational lentiviral gene therapies. More n...

Collaboration focuses on advancing innovation with antibody-drug conjugate (ADC)-based conditioning for lentiviral gene therapies Under the collaboration, AVROBIO and Magenta will jointly evaluate MGTA-117 in conjunction with one or more of AVROBIO’s investigational gene therapi...

Updated data will be presented on first patient dosed in Phase 1/2 clinical trial for cystinosis and first patient treated using plato™ gene therapy platform in Phase 2 Fabry disease clinical trial Company will present new data from preclinical AVR-RD-03 program for Pompe diseas...

Fully automated immunoassay kit designed to simplify and streamline busulfan therapeutic drug monitoring (TDM), potentially reducing turnaround time from hours to minutes and greatly expanding hospital, clinic, medical office and laboratory access to TDM AVROBIO is leading the field b...

The following slide deck was published by AVROBIO, Inc. in conjunction with this Read more ...